Fig. 2From: Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective studyHaemoglobin level (g/dL) during the first 12 months of axitinib treatment. Boxplots represent quartiles and extreme valuesBack to article page